Monday, April 6, 2009
The Wall Street Journal Health Blog's Jacob Goldstein reports,
A bunch of familiar factors are driving this. Payers are being more pushy about getting patients to take generics. As big campaigns like Wal-Mart’s $4 generics deal have made generics more familiar, patients have grown more comfortable with the idea of moving off of branded drugs. Tough economic times and, for many patients, higher co-pays add an economic incentive. And some big name drugs have gone off patent, without being replaced by comparable new blockbusters (Merck’s Zocor — generic simvastatin — comes to mind). . . .